BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26091559)

  • 1. Protein domains of APOL1 and its risk variants.
    Lan X; Wen H; Lederman R; Malhotra A; Mikulak J; Popik W; Skorecki K; Singhal PC
    Exp Mol Pathol; 2015 Aug; 99(1):139-44. PubMed ID: 26091559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
    Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.
    Gutiérrez OM; Judd SE; Irvin MR; Zhi D; Limdi N; Palmer ND; Rich SS; Sale MM; Freedman BI
    Nephrol Dial Transplant; 2016 Apr; 31(4):602-8. PubMed ID: 26152403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.
    Khatua AK; Cheatham AM; Kruzel ED; Singhal PC; Skorecki K; Popik W
    Am J Physiol Cell Physiol; 2015 Jul; 309(1):C22-37. PubMed ID: 25924622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1.
    Sharma AK; Friedman DJ; Pollak MR; Alper SL
    FEBS J; 2016 May; 283(10):1846-62. PubMed ID: 26945671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.
    Olabisi OA; Zhang JY; VerPlank L; Zahler N; DiBartolo S; Heneghan JF; Schlöndorff JS; Suh JH; Yan P; Alper SL; Friedman DJ; Pollak MR
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):830-7. PubMed ID: 26699492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression.
    Hawkins GA; Friedman DJ; Lu L; McWilliams DR; Chou JW; Sajuthi S; Divers J; Parekh RS; Li M; Genovese G; Pollack MR; Hicks PJ; Bowden DW; Ma L; Freedman BI; Langefeld CD
    Am J Nephrol; 2015; 42(2):99-106. PubMed ID: 26343748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease.
    Tzur S; Rosset S; Skorecki K; Wasser WG
    Nephrol Dial Transplant; 2012 Apr; 27(4):1498-505. PubMed ID: 22357707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans.
    Freedman BI; Langefeld CD; Murea M; Ma L; Otvos JD; Turner J; Antinozzi PA; Divers J; Hicks PJ; Bowden DW; Rocco MV; Parks JS
    Nephrol Dial Transplant; 2011 Nov; 26(11):3805-10. PubMed ID: 21931123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of APOL1 G1 and G2 variants in sickle cell disease patients: kidney is the main target.
    Kormann R; Jannot AS; Narjoz C; Ribeil JA; Manceau S; Delville M; Joste V; Prié D; Pouchot J; Thervet E; Courbebaisse M; Arlet JB
    Br J Haematol; 2017 Oct; 179(2):323-335. PubMed ID: 28699644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOL1 Kidney Disease Risk Variants: An Evolving Landscape.
    Dummer PD; Limou S; Rosenberg AZ; Heymann J; Nelson G; Winkler CA; Kopp JB
    Semin Nephrol; 2015 May; 35(3):222-36. PubMed ID: 26215860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein L1 and Kidney Disease in African Americans.
    Friedman DJ; Pollak MR
    Trends Endocrinol Metab; 2016 Apr; 27(4):204-215. PubMed ID: 26947522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequencing rare and common APOL1 coding variants to determine kidney disease risk.
    Limou S; Nelson GW; Lecordier L; An P; O'hUigin CS; David VA; Binns-Roemer EA; Guiblet WM; Oleksyk TK; Pays E; Kopp JB; Winkler CA
    Kidney Int; 2015 Oct; 88(4):754-63. PubMed ID: 25993319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of circulating APOL1 protein complexes in African Americans.
    Weckerle A; Snipes JA; Cheng D; Gebre AK; Reisz JA; Murea M; Shelness GS; Hawkins GA; Furdui CM; Freedman BI; Parks JS; Ma L
    J Lipid Res; 2016 Jan; 57(1):120-30. PubMed ID: 26586272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From man to fish: What can Zebrafish tell us about ApoL1 nephropathy?
    Olabisi O; Al-Romaih K; Henderson J; Tomar R; Drummond I; MacRae C; Pollak M
    Clin Nephrol; 2016 Supplement 1; 86 (2016)(13):114-118. PubMed ID: 27509583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure.
    Freedman BI; Julian BA; Pastan SO; Israni AK; Schladt D; Gautreaux MD; Hauptfeld V; Bray RA; Gebel HM; Kirk AD; Gaston RS; Rogers J; Farney AC; Orlando G; Stratta RJ; Mohan S; Ma L; Langefeld CD; Hicks PJ; Palmer ND; Adams PL; Palanisamy A; Reeves-Daniel AM; Divers J
    Am J Transplant; 2015 Jun; 15(6):1615-22. PubMed ID: 25809272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic association and gene-gene interaction analyses in African American dialysis patients with nondiabetic nephropathy.
    Bostrom MA; Kao WH; Li M; Abboud HE; Adler SG; Iyengar SK; Kimmel PL; Hanson RL; Nicholas SB; Rasooly RS; Sedor JR; Coresh J; Kohn OF; Leehey DJ; Thornley-Brown D; Bottinger EP; Lipkowitz MS; Meoni LA; Klag MJ; Lu L; Hicks PJ; Langefeld CD; Parekh RS; Bowden DW; Freedman BI;
    Am J Kidney Dis; 2012 Feb; 59(2):210-21. PubMed ID: 22119407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOL1 and kidney disease.
    Pollak MR; Genovese G; Friedman DJ
    Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):179-82. PubMed ID: 22257798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease.
    Anyaegbu EI; Shaw AS; Hruska KA; Jain S
    Pediatr Nephrol; 2015 Jun; 30(6):983-9. PubMed ID: 25530085
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Ma L; Chou JW; Snipes JA; Bharadwaj MS; Craddock AL; Cheng D; Weckerle A; Petrovic S; Hicks PJ; Hemal AK; Hawkins GA; Miller LD; Molina AJ; Langefeld CD; Murea M; Parks JS; Freedman BI
    J Am Soc Nephrol; 2017 Apr; 28(4):1093-1105. PubMed ID: 27821631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.